Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 19/20 | 1.00 |
| ▸ | MAOA | P21397 | 2/20 | 1.00 |
| ▸ | MAOB | P27338 | 2/20 | 1.00 |
| ▸ | BCHE | P06276 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ladostigil SCHEMBL3301711 | 1.00 | ACHE (1.00) | ACHEMAOAMAOBBCHE | |
| Ladostigil SCHEMBL3893996 | 1.00 | ACHE (1.00) | ACHEMAOAMAOBBCHE | |
| SCHEMBL13853627 | 0.94 | ACHE (1.00) | ACHEMAOAMAOBBCHE | |
| Ladostigil SCHEMBL2387320 | 0.93 | ACHE (0.87) | ACHEMAOAMAOBBCHE | |
| Ladostigil SCHEMBL30579760 | 0.93 | ACHE (0.87) | ACHEMAOAMAOBBCHE | |
| SCHEMBL12043626 | 0.92 | ACHE (0.84) | ACHEMAOAMAOBBCHE | |
| SCHEMBL13853626 | 0.92 | ACHE (0.84) | ACHEMAOAMAOBBCHE | |
| SCHEMBL3895981 | 0.90 | ACHE (0.98) | ACHEMAOAMAOBBCHE | |
| SCHEMBL3895985 | 0.90 | ACHE (0.98) | ACHEMAOAMAOBBCHE | |
| SCHEMBL13449663 | 0.90 | ACHE (0.98) | ACHEMAOAMAOBBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 544 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719474-A1 | METHOD OF TREATING FIBROTIC-RELATED CONDITION | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-04-08 | — | — | EP | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-20250235641-A1 | DEVICE TO DELIVER A PREDETERMINED AMOUNT OF A SUBSTANCE TO A NATURAL ORIFICE OF THE BODY | APTARGROUP INC. (US) | 2025-07-24 | — | — | US | claimed |
| US-20250205239-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES | ARIBIO CO LTD (KR) | 2025-06-26 | — | — | US | claimed |
| WO-2025134070-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | ARIBIO CO., LTD. (KR) | 2025-06-26 | — | — | WO | claimed |
| US-20250186415-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2025-06-12 | — | — | US | claimed |
| US-20250152547-A1 | COMPOSITIONS FOR DELIVERY OF LADOSTIGIL | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2025-05-15 | — | — | US | claimed |
| EP-4543454-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES | Aribio Co., Ltd (KR) | 2025-04-30 | — | — | EP | claimed |
| CN-119524129-A | Monoamine oxidase inhibitors as modulators of beta cell vulnerability in type 1 diabetes | 乔斯林糖尿病中心 | 2025-02-28 | — | — | CN | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| WO-2022164694-A1 | FIXED DOSE COMBINATION OF CHOLINESTERASE INHIBITOR AND A QUATERNARY AMMONIUM ANTIMUSCARINIC AGENT TO TREAT NEURODEGENERATIVE COGNITIVE DISORDERS | QAAM PHARMACEUTICALS, LLC (US) | 2022-08-04 | — | — | WO | claimed |
| US-20220226276-A1 | COMPOSITIONS FOR DELIVERY OF LADOSTIGIL | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-07-21 | — | — | US | claimed |
| US-11383048-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | SIPNOSE LTD. (IL) | 2022-07-12 | — | — | US | claimed |
| US-20220175818-A1 | Inhibition of Monoamine Oxidase Subtype A (MAOA) Mitigates Cardiovascular Calcification | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2022-06-09 | — | — | US | claimed |
| EP-3980005-A1 | CARABACHOL-BROMONIDINE FORMULATION TO ENHANCE ANTI-PRESBYOPIA EFFECTS | Visus Therapeutics, Inc. (US) | 2022-04-13 | — | — | EP | claimed |
| US-20220107305-A1 | Companion Diagnostics for NSAIDS and Donepezil for Treating Specific Subpopulations of Patients Suffering from Alzheimer's Disease | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH | 2022-04-07 | — | — | US | claimed |
| EP-3976188-A1 | COMPOSITIONS FOR DELIVERY OF LADOSTIGIL | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2022-04-06 | — | — | EP | claimed |
| EP-3965732-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING PRESBYOPIA AND METHODS FOR FABRICATING THEREOF | Harrow IP, LLC (US) | 2022-03-16 | — | — | EP | claimed |
| CN-113993584-A | Compositions for delivering ladostigil | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 2022-01-28 | — | — | CN | claimed |
| EP-1956904-B1 | LOW-DOSE LADOSTIGIL FOR THE TREATMENT OF MILD COGNITIVE IMPAIRMENT | YISSUM RES DEV CO (IL) | 2017-04-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | TNF, PYCARD, VAPA | ACHE 4349/4885MAOA 4117/4885MAOB 4475/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | ACHE 2/4885MAOA 624/4885MAOB 755/4885 |
| US-20220226276-A1 | COMPOSITIONS FOR DELIVERY OF LADOSTIGIL | DDOST, AREG, FABP2 | ACHE 977/4885MAOA 3631/4885MAOB 3685/4885 |
| US-20250152547-A1 | COMPOSITIONS FOR DELIVERY OF LADOSTIGIL | DDOST, AREG, FABP2 | ACHE 977/4885MAOA 3631/4885MAOB 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.